
### [NCIT:C7421](http://purl.obolibrary.org/obo/NCIT_C7421)
**Label:** Rectosigmoid Carcinoma

**Subclasses:** [NCIT:C8636](http://purl.obolibrary.org/obo/NCIT_C8636) (Stage IV Rectosigmoid Cancer AJCC v6), [NCIT:C5015](http://purl.obolibrary.org/obo/NCIT_C5015) (Stage II Rectosigmoid Cancer AJCC v6), [NCIT:C5016](http://purl.obolibrary.org/obo/NCIT_C5016) (Stage I Rectosigmoid Cancer AJCC v6 and v7), [NCIT:C5017](http://purl.obolibrary.org/obo/NCIT_C5017) (Stage 0 Rectosigmoid Cancer AJCC v6 and v7), [NCIT:C43592](http://purl.obolibrary.org/obo/NCIT_C43592) (Rectosigmoid Mucinous Adenocarcinoma), [NCIT:C8634](http://purl.obolibrary.org/obo/NCIT_C8634) (Recurrent Rectosigmoid Carcinoma), [NCIT:C43593](http://purl.obolibrary.org/obo/NCIT_C43593) (Rectosigmoid Signet Ring Cell Carcinoma), [NCIT:C8635](http://purl.obolibrary.org/obo/NCIT_C8635) (Stage III Rectosigmoid Cancer AJCC v6), [NCIT:C43584](http://purl.obolibrary.org/obo/NCIT_C43584) (Rectosigmoid Adenocarcinoma), [NCIT:C91226](http://purl.obolibrary.org/obo/NCIT_C91226) (Rectosigmoid Cancer by AJCC v7 Stage), [NCIT:C89992](http://purl.obolibrary.org/obo/NCIT_C89992) (Stage II Rectosigmoid Cancer AJCC v7), [NCIT:C89997](http://purl.obolibrary.org/obo/NCIT_C89997) (Stage III Rectosigmoid Cancer AJCC v7), [NCIT:C90509](http://purl.obolibrary.org/obo/NCIT_C90509) (Rectosigmoid Cancer by AJCC v6 Stage), [NCIT:C90019](http://purl.obolibrary.org/obo/NCIT_C90019) (Stage IV Rectosigmoid Cancer AJCC v7), 

**Class expressions from DL-Learner:**

- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C2987](http://purl.obolibrary.org/obo/NCIT_C2987) (Diarrhea))) 64.29%
- [NCIT:C60661](http://purl.obolibrary.org/obo/NCIT_C60661) (Tenesmus) 57.14%
- [NCIT:C37930](http://purl.obolibrary.org/obo/NCIT_C37930) (Constipation) 57.14%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39602](http://purl.obolibrary.org/obo/NCIT_C39602) (Pleomorphic Medium-Sized to Large T-Lymphocyte))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39600](http://purl.obolibrary.org/obo/NCIT_C39600) (Neoplastic Medium-Sized T-Lymphocyte))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39598](http://purl.obolibrary.org/obo/NCIT_C39598) (CEBPA Gene))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39597](http://purl.obolibrary.org/obo/NCIT_C39597) (PRKCB Gene))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39596](http://purl.obolibrary.org/obo/NCIT_C39596) (CCND2 Gene))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39594](http://purl.obolibrary.org/obo/NCIT_C39594) (Skin Rash))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39593](http://purl.obolibrary.org/obo/NCIT_C39593) (Peripheral Blood Involvement))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39589](http://purl.obolibrary.org/obo/NCIT_C39589) (Angioinvasion))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39588](http://purl.obolibrary.org/obo/NCIT_C39588) (Serum Soluble Fas Ligand Level Increased))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39586](http://purl.obolibrary.org/obo/NCIT_C39586) (T-Cell Large Granular Lymphocyte Leukemia Expressing the T-Cell Receptor Gamma-Delta))) 55.11%
- [NCIT:C5034](http://purl.obolibrary.org/obo/NCIT_C5034) (Disturbance in Bowel Function) and (not ([NCIT:C39584](http://purl.obolibrary.org/obo/NCIT_C39584) (T-Cell Large Granular Lymphocyte Leukemia, Common Variant))) 55.11%


